IRIS
ALTAVILLA, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.288
EU - Europa 4.807
AS - Asia 807
SA - Sud America 12
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 4
AF - Africa 1
Totale 10.927
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.279
IE - Irlanda 1.309
SE - Svezia 1.223
CN - Cina 732
IT - Italia 703
UA - Ucraina 463
DE - Germania 293
GB - Regno Unito 234
FI - Finlandia 202
PL - Polonia 155
BE - Belgio 63
FR - Francia 61
IN - India 39
RU - Federazione Russa 37
VN - Vietnam 18
AT - Austria 15
ES - Italia 10
BR - Brasile 9
IR - Iran 9
NL - Olanda 9
CA - Canada 7
AU - Australia 6
CH - Svizzera 5
CZ - Repubblica Ceca 3
NO - Norvegia 3
RO - Romania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BG - Bulgaria 2
CL - Cile 2
EU - Europa 2
GR - Grecia 2
HR - Croazia 2
LV - Lettonia 2
MX - Messico 2
NZ - Nuova Zelanda 2
SG - Singapore 2
SK - Slovacchia (Repubblica Slovacca) 2
AL - Albania 1
AM - Armenia 1
BD - Bangladesh 1
CO - Colombia 1
DK - Danimarca 1
EE - Estonia 1
HK - Hong Kong 1
HU - Ungheria 1
IQ - Iraq 1
LT - Lituania 1
MM - Myanmar 1
RS - Serbia 1
SC - Seychelles 1
TH - Thailandia 1
TR - Turchia 1
Totale 10.927
Salva come PNG Salva come JPEG
Città #
Dublin 1.309
Chandler 1.006
Jacksonville 941
Nyköping 691
Beijing 302
Ashburn 270
Dearborn 251
Ann Arbor 244
Princeton 220
Medford 201
Cambridge 199
Warsaw 155
Des Moines 152
Messina 144
Boardman 116
New York 113
Lancaster 110
Jinan 77
Woodbridge 67
Brussels 60
Shenyang 52
Wilmington 49
San Mateo 45
Tianjin 39
Nanjing 35
Houston 34
Hebei 27
Pune 26
Zhengzhou 25
Catania 23
Rome 22
Seattle 21
Washington 21
Nanchang 20
Haikou 18
Dong Ket 17
Ningbo 17
Norwalk 17
Bremen 15
Scarsdale 15
Vienna 15
Changsha 13
Hangzhou 13
Jiaxing 13
Redwood City 13
Taizhou 13
Milan 12
Leawood 11
Saint Petersburg 10
Helsinki 9
Auburn Hills 8
Guangzhou 8
Modica 8
Fuzhou 7
Taiyuan 7
Augusta 6
Chicago 6
Clearwater 6
London 6
Monmouth Junction 6
Florence 5
Lanzhou 5
Novokuznetsk 5
Vitoria 5
Ardabil 4
Brescia 4
Kemerovo 4
La Spezia 4
Montréal 4
Mumbai 4
Philadelphia 4
Porto Alegre 4
Redmond 4
São Paulo 4
Tappahannock 4
Atlanta 3
Belpasso 3
Caserta 3
Edinburgh 3
Imola 3
Kunming 3
Las Vegas 3
Los Angeles 3
Mili Marina 3
Napoli 3
New Delhi 3
Northampton 3
Padova 3
Phoenix 3
San Giovanni Rotondo 3
Sassari 3
Savona 3
Sona 3
Aci Castello 2
Albano Laziale 2
Ameno 2
Avezzano 2
Barcelona 2
Bari 2
Brno 2
Totale 7.488
Salva come PNG Salva come JPEG
Nome #
PARAGANGLIOMA MALIGNO DEL CORPO CAROTIDEO.Rilievi Clinici, Morfologici, Istochimici E Ultrastrutturali Su Un Caso. 361
Su di un caso di pseudomyxoma peritonei con diffusione spontanea alla pleura. 125
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy 102
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued? 95
Liver dysfunction in hcv infected patients with CD20-Positive B-Cell Lymphoma undergoing rituximab combination chemotherapy 89
Studio anatomo-clinico di due casi di sarcoma sinoviale monofasico del ginocchio 84
Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. 82
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 80
Epirubucin (EPI) and Paclitaxel (TAX) in advanced breast cancer.a phase II studyi 80
Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. 79
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. 79
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy 78
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation 77
Increased annual frequency of Hashimoto's thyroiditis between years 1988 and 2007 at a cytological unit of Sicily. 76
Razionale e tecniche della chirurgia citoriduttiva e della chemioipertermia peritoneale. 75
Annual increase in the frequency of papillary thyroid carcinoma as diagnosed by fine-needle aspiration at a cytology unit in Sicily. 74
Antiblastic treatment of advanced cervical carcinoma and its recurrences: assessment of four different polychemotherapies used for a decade. 73
Liquid biopsy for lung cancer early detection 73
Bone and lymph node metastases from occult mammary carcinoma: a case report of carcinoma of unknown primary (CUP) Syndrome 72
Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST 71
[Serum levels of copper and zinc in patients with lung cancer] 71
A novel HPLC method for the determination of mitoxantrone in pharmaceutical formulations. 70
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 70
ANALYSES AND DETERMINATION OF LONIDAMINE RELEASE FROM PHARMACEUTICAL FORMULATION. 69
HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. 69
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer 69
Trattamento palliativo dei tumori del retto-sigma mediante elettrocoagulazione endoscopica.” 68
The treatment of peritoneal carcinomatosis in elderly patients. 68
Cancer screening in HIV-infected patients: early diagnosis in a high-risk population 68
Mechanical dispersion and cardiotoxicity in patients who underwent chemotherapy for breast cancer: an echocardiographic study 68
SUBCUTANEOUS LOW-DOSE ALEMTUZUMAB AS FIRST LINE THERAPY FOR ELDERLY CLL PATIENTS WITH DELETION OF 17p 67
A study of endometrial adenocarcinoma treated with tamoxifen by scanning and transmission electron microscopy. 67
Analytical profile and release of lonidamine from pharmaceutical formulation 67
Myocardial damage pattern in women with breast cancer who underwent chemotherapy: strain polar maps analysis 67
Surgical treatment for congestive heart failure with autologous adult stem cell transplantation 66
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 66
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 66
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 66
Alectinib: A selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer 66
Targeted drugs in small-cell lung cancer 66
Applications of genomics in NSCLC 65
Phase II study paclitaxel (PTX) and cisplatin (Cis) in advanced and recurrent head&neck cancer 64
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases 64
A randomized factorial trial of sequential doxrubicina and CMF vs CMF and chemoterapy alone vs chemoterapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer 64
INFLUENCE OF CYP2C9 POLYMORPHISM IN LUNG CANCER SUSCEPTIBILITY 63
An acute-leukaemia-like picture due to breast carcinoma cells. 63
One-year follow up assessment of chemotherapy-related vascular toxicity: an arterial stiffness study 63
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 63
A PHASE III RANDOMIZED TRIAL COMPARING THREE PLATINUM-BASED DOUBLETS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): IMPACT OF PS=2 VS 0 OR 1 AND AGE ³70 VS <70 ON CHEMOTHERAPY OUTCOME 62
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study 62
ANALYSES AND DETERMINATION OF LONIDAMINE RELEASE FROM PHARMACEUTICAL FORMULATION. 62
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: Understanding transforming growth factor-beta role 62
Left atrial function in patients undergoing chemotherapy: additional value of 2D longitudinal strain 62
Analisi dello stato di metilazione del promoter di O6-methylguanine DNA methyltransferase (MGMT) e TMS1/ASC nei gliomi cerebrali diffusi di basso grado: possibili implicazioni cliniche e prognostiche. 62
Gemcitabine (GEM) and cisplatin (Cis) in advanced/metastatic transitional cell carcinoma (TCC) of bladder: Phase II study 61
Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck 61
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. 61
Transpersonal integrated interventions to improve quality of life in cancer patients in all stages of disease 60
Treatment of advanced and/or metastatic epidermoid carcinoma of the head and neck: an effective combination chemotherapy with bleomycin, methotrexate and ftorafur. 60
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 60
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 60
Early assessment of chemotherapy-related cardiovascular toxicity in patients with breast cancer 60
A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin 59
The treatment of recurrent and metastatic cervical carcinoma. Evaluation of an antiblastic combination of methotrexate-adriamycin-bleomycin (MAB) 59
Endocrine toxicity of immune checkpoint inhibitors (anti-PD-1/PD-L1) in advanced cancer 59
Espressione differenziale di un panel di miRNA in tumori cerebrali astrogliali con diverso grado di malignità. 59
Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. 58
Retrospective analiysis of P-STAT6 expression as predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 58
Sternal metastasis as initial presentation of a unknown rectal cancer 58
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 58
Peritoneal carcinomatosis of colorectal origin. 58
Clodronate and radiotherapy for the treatment of osteolysis caused by metastasis of breast carcinoma and non-small cell lung carcinoma. A retrospective study 57
Relapsed or refractory extranodal DLBCL treated with lenalidomide: A single center study 57
90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL OF INTERMEDIATE/HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS NOT RESPONDING ADEQUATELY TO FIRST 57
Phase II study Paclitaxel (PTX) and Cisplatin (Cis) in advanced and recurrent head and neck cancer 56
A PHASE II STUDY (21 day regimen) OF GEMCITABINE (Gem) AND CISPLATIN ( Cis) IN ADVANCED/METASTATIC TRANSITIONAL CELL CARCINOMA (TTC) OF BLADDER 56
Microvessels density evaluation in human meningiomas: an immunohistochemical investigation by the specific marker for neoangiogenesis CD105 (Endoglin). 56
Thyroid function, autoimmunity and nodules in hematological malignancies 56
[(186)Re]HEDP in the palliation of painful bone metastases from cancers otherthan prostate and breast. 54
Transpersonal Therapy Combined with Best Supportive Care In Hospice Improve Patient’s Quality of Life and Quality Of Death 54
Psycho-Neuro-Endocrine-Immune System (PNEI) Involvement as Prognostic Marker in Breast Cancer Patients at 10 Years of Follow Up 54
Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer 54
ZD 1839 IRESSA IN HEAVELY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) ASSESSMENT OF TOLERABILITY AND THE CLINICAL BENEFIT 53
Behavior of serum sialic acid levels at various stages of neoplastic disease 53
null 53
Amplification and overexpression of the PSMB5 gene contribute to Bortezomib resistance in re-treatment of patients with Multiple Myeloma 53
Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy 53
Unusual relapse of hepatocellular carcinoma 53
Analysis of multilayer strain and myocardial work in patients undergoing chemotherapy treatment: a 12 months follow-up 53
First Line Chemotherapy with Oral Vinorelbine (oV) in Elderly Hormone-Refractory Prostate Cancer (HRPC) Patients (pts 52
Effects of synthetic salmon calcitonin in the treatment of bone lesions of the neoplastic type 52
Pharmacogenomics in non-small-cell lung cancer chemotherapy. 51
Venous damage prevention by defibrotide in vinorelbine-treated patients 51
From the bench to the bed: individualizing treatment in non-small-cell lungcancer 51
Older people with non small cell lung cancer in clinical stage IIIA and co-morbid conditions - Is curative irradiation feasible? Final results of a prospective study 51
La farmacogenomica nei tumori del polmone 51
Severe pulmonary complications after bortezomib treatment for multiple myeloma: An unrecognized pulmonary vasculitis? 51
Gemcitabine as single agent in the treatment of elderly patients with advanced non small cell lung cancer 51
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? 51
PHASE II STUDY PACLITAXEL AND CISPLATIN IN ADVANCED AND RECURRENT HEAD & NECK CANCER 50
Totale 6.713
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.012
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.012
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201950 0 0 0 0 0 0 0 0 0 18 21 11
2019/20201.754 277 130 10 126 38 238 221 177 34 213 260 30
2020/20211.610 169 18 339 114 186 170 48 148 64 169 118 67
2021/20221.555 10 224 45 40 59 20 84 61 31 244 269 468
2022/20233.927 312 372 174 289 306 401 57 236 1.613 22 96 49
2023/2024799 76 128 66 115 74 261 23 45 3 8 0 0
Totale 11.204